Compare BCAB & SRBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCAB | SRBK |
|---|---|---|
| Founded | 2007 | 1887 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.6M | 123.7M |
| IPO Year | 2020 | N/A |
| Metric | BCAB | SRBK |
|---|---|---|
| Price | $0.54 | $15.82 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $1.00 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 37.8K |
| Earning Date | 11-13-2025 | 01-30-2026 |
| Dividend Yield | N/A | ★ 1.26% |
| EPS Growth | N/A | ★ 374.69 |
| EPS | N/A | ★ 0.54 |
| Revenue | N/A | ★ $31,130,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $29.31 |
| Revenue Growth | N/A | ★ 0.85 |
| 52 Week Low | $0.24 | $11.36 |
| 52 Week High | $1.43 | $17.11 |
| Indicator | BCAB | SRBK |
|---|---|---|
| Relative Strength Index (RSI) | 35.75 | 48.79 |
| Support Level | $0.63 | $16.12 |
| Resistance Level | $0.82 | $16.34 |
| Average True Range (ATR) | 0.11 | 0.39 |
| MACD | -0.02 | -0.14 |
| Stochastic Oscillator | 1.07 | 22.15 |
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
SR Bancorp Inc principal business is to acquire deposits from individuals and businesses in the communities surrounding offices and to use these deposits to fund loans.